News overview
News
5 August 2021
Absence of stem cells in pancreas changes view on pancreatic cancer
New research by Oncode Investigator Louis Vermeulen and co-investigator Maarten Bijlsma shows that there are no stem cells in the pancreas. These unexpected findings potentially have major implications for pancreatic cancer research, since stem cells are often at the root of tumor development. This research was published today in the leading journal Cell Stem Cell.
Bianca-OliviaNita
<span>Bianca-Olivia</span><span>Nita</span>
News
27 July 2021
Antibodies with a mission: what the Utrecht Monoclonal Antibody Facility (UMab) can do for you
As part of the Infrastructure and Technology programme, Oncode started a collaborative project together with Oncode Investigator Linde Meyaard (UMCU) and Jeanette Leusen (head of the Utrecht Monoclonal Antibody Facility (UMab)) with the goal of being able to offer Oncode Investigators the opportunity to produce high quality antibodies (targeted against membrane proteins). Oncode is now looking to fund a total of 4 Oncode Investigators to develop monoclonal antibodies potentially suited for clinical applications in oncology, directed against their membrane target of choice.
Bianca-OliviaNita
<span>Bianca-Olivia</span><span>Nita</span>
News
20 July 2021
Oncode collaboration results in a new mathematical method that can predict cancer survival based on genetic changes
As cancer survival rates vary widely, Oncode Researcher Daniel Miedema from Oncode Investigator Louis Vermeulen’s lab (Amsterdam UMC), in collaboration with the teams of Oncode Investigators Hugo Snippert (UMC Utrecht) and Geert Kops (Hubrecht Institute) has developed a mathematical method to predict survival based on genetic changes in cancer. The results of this study are now published in Nature Communications.
Bianca-OliviaNita
<span>Bianca-Olivia</span><span>Nita</span>
Story
16 July 2021
Beyond the p values: guide to building your possibly first biotech
Oncode Oncology Bridge Fund manager Shobhit Dhawan on the art and challenges of linking researchers, investors and industry, and turning exciting research projects into successful companies.
Bianca-OliviaNita
<span>Bianca-Olivia</span><span>Nita</span>
News
14 July 2021
Oncode Investigators Hugo Snippert and Jarno Drost receive NWO-Vidi grant
Just announced: The Dutch Research Council has awarded Oncode Investigators Hugo Snippert (UMCU) and Jarno Drost (Princess Máxima Center for pediatric oncology) a NWO-Vidi grant worth 800.000 Euros. The Vidi grant is part of the NWO Talent Programme and will enable them to develop their own innovative line of research in the coming five years.
Bianca-OliviaNita
<span>Bianca-Olivia</span><span>Nita</span>
News
12 July 2021
Oncode and NKI spinout a new company targeting senescence in oncology, led by Rene Bernards
Over the last 5 years Oncode Investigator Rene Bernards’ laboratory at the NKI has been focused on understanding senescence and its role in tumour biology. This has now culminated in a new company that will take the next step – discover and develop therapeutics that exploit senescence to target tumours.
Bianca-OliviaNita
<span>Bianca-Olivia</span><span>Nita</span>
In the spotlight
22 July 2020
COVID-19: updates for the Oncode research community
As an Oncode researcher, you might have questions about how we are mitigating the impact of the current COVID-19 crisis on our programmes, projects and funding. We created a Q&A with the answers these questions and plan to update this Q&A regularly.
ElizeBrolsma
<span>Elize</span><span>Brolsma</span>
Elize is part of Oncode’s communication team. She has over 10 years of experience in the com-munication industry, both for commercial and non-profit organisations. After obtaining her bache-lor and master degree in communication at Utrecht University, Elize worked as a communication professional at a research institute, PR agency, law firm and internet company. She has a strong focus on external communications and Public Relations.
At Oncode - together with her colleagues - Elize produces the monthly newsletters for Oncode Investigators & Researchers and the Oncode digital magazine. She publishes content for the Oncode website and is responsible for all social media channels. She enjoys discussing science with researchers and support them in their outreach.
News
1 July 2021
Unraveling the genetic evolution of individual tumor cells
The research group of Hugo Snippert reports the first detailed insights into the pace and patterns by which genetic alterations are generated by tumors. The results appear today in the leading journal Nature Genetics and shed new light on the origin of colon tumors.
News
30 June 2021
Oncode Investigator Jarno Drost and his team part of joint research that uncovers the cellular signatures of kidney tumors
Oncode Investigator Jarno Drost and his team at the Princess Maxima Centre in collaboration with researchers at the Wellcome Sanger Institute and Great Ormond Street Hospital (GOSH) have uncovered the origins of seven types of kidney cancer including several rare subtypes. Their findings confirm that these cancers have their origin in specific forms of developmental cells present in the maturing fetus. The study has recently been published in Nature Communications.
News
29 June 2021
Fully online, always together: looking back at the third edition of Oncode’s CGC Annual Scientific Meeting
As preparations were in progress for our third Oncode CGC Annual Scientific Meeting, the COVID-19 governmental restrictions kept changing. We had to take some decisions in this shifting environment and the best option was to broadcast the event from a studio and have everything fully online. And even though we did not get a chance to see each other in real life, this year’s edition had a unique flavour of its own. We look back at a successful and interesting event, packed with science and online networking.
ElizeBrolsma
<span>Elize</span><span>Brolsma</span>
Elize is part of Oncode’s communication team. She has over 10 years of experience in the com-munication industry, both for commercial and non-profit organisations. After obtaining her bache-lor and master degree in communication at Utrecht University, Elize worked as a communication professional at a research institute, PR agency, law firm and internet company. She has a strong focus on external communications and Public Relations.
At Oncode - together with her colleagues - Elize produces the monthly newsletters for Oncode Investigators & Researchers and the Oncode digital magazine. She publishes content for the Oncode website and is responsible for all social media channels. She enjoys discussing science with researchers and support them in their outreach.
News
22 June 2021
Research/Industry collaboration on potential anti-cancer treatment published in eLife
Oncode Investigator Linde Meyaard, UMC Utrecht, identified the inhibitory immune receptor LAIR-1 and has been working on it for over 20 years. Biotech company NextCure (USA) developed NC410, a product candidate based on the LAIR family of molecules, and reached out to Linde to collaborate. Their joint paper Cancer immunotherapy by NC410, a LAIR-2 Fc protein blocking human LAIR-collagen interaction is now published in eLife.
ElizeBrolsma
<span>Elize</span><span>Brolsma</span>
Elize is part of Oncode’s communication team. She has over 10 years of experience in the com-munication industry, both for commercial and non-profit organisations. After obtaining her bache-lor and master degree in communication at Utrecht University, Elize worked as a communication professional at a research institute, PR agency, law firm and internet company. She has a strong focus on external communications and Public Relations.
At Oncode - together with her colleagues - Elize produces the monthly newsletters for Oncode Investigators & Researchers and the Oncode digital magazine. She publishes content for the Oncode website and is responsible for all social media channels. She enjoys discussing science with researchers and support them in their outreach.
Scroll for more